The PI3Kinase p55 gamma antibody is a crucial tool for studying the regulatory subunit of class IA phosphatidylinositol 3-kinases (PI3Ks), which play pivotal roles in cellular signaling. PI3Ks are heterodimeric enzymes consisting of a catalytic subunit (e.g., p110) and a regulatory subunit. The p55 gamma subunit, encoded by the *PIK3R3* gene, is one of several regulatory isoforms (p85α, p55α, p50α, p85β, p55γ) that stabilize the catalytic subunit and modulate lipid kinase activity. Unlike p85α, p55 gamma lacks certain domains, resulting in distinct regulatory functions. It is expressed in specific tissues, including immune cells, and participates in signaling pathways governing cell growth, survival, metabolism, and immune responses.
Antibodies targeting p55 gamma enable researchers to investigate its expression, localization, and interactions in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Dysregulation of PI3K signaling, including p55 gamma-associated pathways, is implicated in cancers, immune disorders, and metabolic diseases. For example, altered p55 gamma expression may influence tumor progression or insulin resistance by affecting downstream effectors like AKT and mTOR. Additionally, studies suggest its role in fine-tuning immune receptor signaling, such as in B-cell activation. These antibodies help elucidate mechanisms of PI3K isoform-specific regulation, aiding drug development and biomarker discovery for diseases linked to PI3K pathway hyperactivity. Their specificity ensures accurate detection amidst closely related regulatory subunits.